Edmond de Rothschild Investment Partners participates in the CHF 18 Million Series B financing of OncoEthix with its new fund BioDiscovery 4
(Thomson Reuters ONE) -
Edmond de Rothschild Investment Partners /
Edmond de Rothschild Investment Partners participates in the CHF 18 Million
Series B financing of OncoEthix with its new fund BioDiscovery 4
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Paris, France - Edmond de Rothschild Investment Partners announces the third
investment of BioDiscovery 4, its fourth fund dedicated to Life Sciences,
through its participation in the Series B financing round of OncoEthix.
OncoEthix is a Swiss-based oncology drug development company founded in 2009.
Edmond de Rothschild Investment Partners participated in the Series B financing
round of CHF 18 million alongside SV Life Sciences and existing investors Index
Ventures and Endeavour Vision.
The funds will be used for the clinical development of OTX015, a small molecule
inhibitor targeting BET bromodomain proteins 2/3/4. The BET proteins are
considered potential cancer targets because of their pivotal role in regulating
the transcription of growth-promoting and cell cycle regulators, especially c-
MYC. A two strata Phase 1 study in acute leukemia and other hematologic
malignancies was started in January 2013.
Raphaël Wisniewski, Partner at Edmond de Rothschild Investment Partners,
commented: "We are very excited that our new fund Biodiscovery 4 can support
this promising company and that our Venture Partner Dr Thierry Hercend has been
appointed as an industry expert to OncoEthix. OTX015 is one of the first
molecules and likely the best, in the emerging class of BET bromodomain
inhibitors. We have been impressed by the team's achievements to date and are
confident that in their expert hands OTX015 has the potential to become a major
drug in oncology."
Bertrand Damour, CEO of OncoEthix added: "We are delighted and very fortunate to
have attracted Edmond de Rothschild Investment Partners as well as other blue-
chip life science investors and we believe this financing will support an
exciting next chapter in the development of OTX015."
About Edmond de Rothschild Investment Partners
Paris-based Edmond de Rothschild Investment Partners is dedicated to minority
investments into privately-owned companies. It currently has close to ?1 billion
under management which is being invested primarily as life sciences venture
capital and growth capital.
Its Life Sciences Team of eight professionals brings together over 60 years of
experience in the Life Science industry and more than 100 years of private
equity and venture capital experience. The team has ?355 million under
management through its Biodiscovery franchise.
BioDiscovery Funds, including BioDiscovery 4, are venture capital funds
registered via the fast-track procedure. These funds are not authorized by the
Autorité des Marchés Financiers and may adopt special investment rules.
BioDiscovery 4, a Venture Capital Fund registered via the fast-track procedure,
invests mainly in private companies, which involves specific risks such as a
risk of capital loss, a discretionary management risk and a liquidity risk.
Edmond de Rothschild Investment Partners is the private equity affiliate of the
Edmond de Rothschild Group, which is specialised in asset management and private
banking (EUR 130bn under management, 2,900 employees and 30 offices throughout
the world). Founded in 1953, the Group has been chaired since 1997 by Baron
Benjamin de Rothschild.
About OncoEthix
Founded in 2009, OncoEthix is a Swiss-based privately held biotechnology Company
that is developing a small portfolio of oncology drug candidates. The Company's
lead product OTX015, is an orally administered synthetic small molecule targeted
to BET bromodomain proteins 2/3/4. OTX015 was in-licensed from Mitsubishi Tanabe
Pharma Corporation in March 2012 following completion of Phase I clinical
studies in healthy volunteers.
OncoEthix has raised a total of 28 Million CHF (~US$30 Million) in venture
capital to date: investors include Index Ventures, Endeavour Vision, SV Life
Sciences and Edmond de Rothschild Investment Partners.
For further information, please visit www.oncoethix.com
Contacts
Edmond de Rothschild Investment Partners
Raphaël Wisniewski
Raphael.WISNIEWSKI(at)lcfr.fr
Tel: +33 1 40 17 27 69
OncoEthix
Bertrand Damour, CEO
bertrand.damour(at)oncoethix.com
Press Release (PDF):
http://hugin.info/139296/R/1715063/569749.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Edmond de Rothschild Investment Partners via Thomson Reuters ONE
[HUG#1715063]
Unternehmensinformation / Kurzprofil:
Datum: 09.07.2013 - 09:00 Uhr
Sprache: Deutsch
News-ID 276494
Anzahl Zeichen: 5780
contact information:
Town:
Paris
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 182 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Edmond de Rothschild Investment Partners participates in the CHF 18 Million Series B financing of OncoEthix with its new fund BioDiscovery 4"
steht unter der journalistisch-redaktionellen Verantwortung von
Edmond de Rothschild Investment Partners (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
